Clinical Development

Clinical development of varoglutamstat

Phase 1 – Completed

Phase 2a SAPHIR – Completed

Phase 2b VIVIAD – EU Study, fully recruited

Phase 2a/b VIVA-MIND – US Study, recruiting

Safety and tolerability in healthy volunteers

Varoglutamstat is well-tolerated

Link to clinicaltrials.gov

Safety and tolerability in patients with early AD

3-month treatment significantly improved working memory (One Back Test) and synaptic function (EEG), as well as neuroinflammation (CSF Biomarkers)

Link to clinicaltrials.gov

Safety, tolerability and efficacy in Patients MCI or mild AD

Endpoints: safety, attention/ working memory, NTB, biomarkers

Link to clinicaltrials.gov

Efficacy and safety in patients with early AD

Endpoints: safety, attention/ working memory, CDR-SB biomarkers

Study with adaptive dose finding phase and potential for seamless expansion into confirmatory Phase 3 study